Table 4.
Summary of management of all reported cases of 36 patients with anti-mGluR1 encephalitis.
| Case Number | References | Therapy | Remission | Relapses | Antibodies | Duration of follow-up (Month) | Disability | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucocorticoids | IVIg | PLEX | Rituximab | Tacrolimus | Azathioprine | Mycophenolate mofetil | Cyclophosphamide | Hydroxychloroquine | |||||||
| 1 | Sillevis Smitt et al. (11) | Yes | Yes | Yes | - | - | - | - | - | - | Complete | None | Resolved | 7 | No |
| 2 | Sillevis Smitt et al. (11) | - | - | Yes | - | - | - | - | - | - | No | None | Persistent | 24 | Yes |
| 3 | Marignier et al. (10) | Yes | Yes | - | - | - | - | Yes | - | - | Partial | None | Persistent | 40 | Yes |
| 4 | Lancaster et al. (9) | Yes | - | - | - | - | - | - | - | - | No | None | NA | 36 | Yes |
| 5 | Iorio et al. (20) | Yes | Yes | - | - | - | - | - | - | - | Partial | None | NA | 36 | No |
| 6 | Lopez-Chiriboga et al. (4) | Yes | - | - | Yes | - | - | - | - | - | Partial | One | NA | 17 | Yes |
| 7 | Lopez-Chiriboga et al. (4) | Yes | Yes | - | - | - | - | - | - | - | No | None | NA | 9 | NA |
| 8 | Lopez-Chiriboga et al. (4) | - | Yes | - | - | - | - | - | - | - | Partial | One | NA | 24 | Yes |
| 9 | Lopez-Chiriboga et al. (4) | Yes | Yes | - | - | - | - | - | - | - | Partial | None | NA | 27 | Yes |
| 10 | Lopez-Chiriboga et al. (4) | Yes | Yes | Yes | - | - | - | - | - | - | Partial | None | NA | 11 | Yes |
| 11 | Lopez-Chiriboga et al. (4) | Yes | - | - | - | - | - | - | - | - | Partial | One | NA | 168 | Yes |
| 12 | Lopez-Chiriboga et al. (4) | - | - | - | - | - | - | - | - | - | Partial | None | NA | 6 | Yes |
| 13 | Lopez-Chiriboga et al. (4) | - | - | - | - | - | - | - | - | - | No | None | NA | 4 | Yes |
| 14 | Lopez-Chiriboga et al. (4) | - | - | - | - | - | - | - | - | - | No | None | NA | 60 | Yes |
| 15 | Lopez-Chiriboga et al. (4) | Yes | - | - | - | - | - | - | - | - | Partial | None | NA | 6 | No |
| 16 | Lopez-Chiriboga et al. (4) | - | - | - | Yes | - | - | - | - | - | No | None | NA | 4 | Yes |
| 17 | Yoshikura et al. (2) | Yes | Yes | Yes | Yes | - | Yes | - | - | - | Partial | Three | Persistent | 67 | Yes |
| 18 | Pedroso et al. (21) | Yes | Yes | - | Yes | - | - | - | Yes | - | NA | None | NA | 46 | NA |
| 19 | Christ et al. (12) | Yes | Yes | - | Yes | Yes | - | - | - | - | Partial | One | Persistent | 24 | Yes |
| 20 | Gollion et al. (13) | Yes | Yes | - | - | - | - | - | - | - | Complete | None | Persistent | 10 | No |
| 21 | Chaumont et al. (14) | - | Yes | - | Yes | - | - | - | Yes | - | Partial | None | NA | 12 | Yes |
| 22 | Spatola et al. (15) | Yes | -Yes | - | Yes | - | - | - | Yes | - | No | None | NA | 55 | Yes |
| 23 | Spatola et al. (15) | - | Yes | - | Yes | - | - | - | Yes | - | Partial | None | NA | 12 | No |
| 24 | Spatola et al. (15) | Yes | Yes | - | Yes | - | Yes | - | Yes | - | Partial | None | NA | 20 | Yes |
| 25 | Spatola et al. (15) | - | - | - | - | - | - | - | - | - | No | None | NA | 168 | Yes |
| 26 | Spatola et al. (15) | Yes | - | - | - | - | - | Yes | - | Yes | Complete | One | NA | 120 | No |
| 27 | Spatola et al. (15) | Yes | - | - | - | - | - | Yes | - | - | Partial | None | NA | 90 | Yes |
| 28 | Spatola et al. (15) | Yes | - | - | - | - | - | - | - | - | Complete | None | NA | 66 | No |
| 29 | Spatola et al. (15) | - | - | - | - | - | - | - | - | - | Partial | None | NA | 6 | Yes |
| 30 | Spatola et al. (15) | - | Yes | - | - | - | Yes | - | - | - | Partial | None | NA | 84 | No |
| 31 | Spatola et al. (15) | Yes | Yes | - | - | - | - | - | - | - | Complete | None | NA | 2.5 | No |
| 32 | Bien et al. (16) | Yes | - | - | - | - | - | - | - | - | Complete | None | Persistent | 9.5 | No |
| 33 | Chandler et al. (17) | Yes | Yes | - | - | - | - | - | - | - | Complete | None | NA | 17 | No |
| 34 | Vinke et al. (18) | - | Yes | - | - | - | Yes | Yes | - | - | Partial | Yes* | Persistent | 67 | No |
| 35 | Goh et al. (19) | Yes | - | - | - | - | - | - | - | - | Complete | None | NA | 3 | No |
| 36 | Current case | Yes | Yes | Yes | Yes | - | Yes | - | - | - | Partial | One | Persistent | 61 | No |
IVIg, intravenous immunoglobulin; PLEX, plasma exchange; NA, not applicable
*
Number of relapses was not mentioned.